Genitourinary Drugs Market Size, Industry Analysis Report, Regional Outlook, Application Growth Potential, Competitive Market Growth & Forecast, 2021 – 2027
Report ID: GMI1382
Genitourinary Drugs Market size will witness a considerable growth over the forecast period.
Increasing prevalence of genitourinary disorders, rising disposable incomes, and constant improvements in healthcare infrastructure will drive genitourinary drugs market over the forecast timeframe.
Patients with diabetes are highly susceptible to suffer from urinary tract infections. Women are more disposed to this problem due to the short length of urethra that facilitates easier entry of microorganisms. Global prevalence of diabetes is projected to reach up to 552 million by 2030 from 366 million in 2011, as per the statistics by International Diabetes Federation. Tremendous growth in diabetes prevalence should also boost the demand for genitourinary drugs over the coming years.
Lack of therapy compliance and continual patent expirations may hamper the overall genitourinary drugs market growth. Invasion of a wide range of generics by major- and medium-sized pharmaceutical companies is likely to constrain the industry growth.
Prostate cancer contributed to over 25% revenue share in 2015. A wide range of therapeutics, such as radiopharmaceuticals, immunotherapy medication, and anti-neoplastic agents, available to treat prostate cancer will drive this segment’s growth. According to National Cancer Institute (NCI), the total number of new prostate cancer cases between 2009 to 2013 were 129.4 per 100,000 men every year.
Urinary Tract Infections (UTIs) affect more than 150 million people every year worldwide, resulting in direct healthcare expenses of over USD 6 billion. Around 2.4 percent of women and men will be detected with bladder cancer at some point during their lifetime.
Hormonal therapy dominated the segment in 2015 due to increasing usage of medicines; however, anti-infective drugs should witness a healthy growth over the forecast period with increasing rate of urinary tract infections. The presence of an extensive drug pipeline for reproductive disorders in women may boost sales of the gynecological products over the coming years.
U.S. genitourinary drugs market size held a large share of the global genitourinary drugs in 2015 due to robust healthcare infrastructure, growing awareness, and technological advancements in the development of genitourinary drugs.
Canada genitourinary drugs market share is driving due to the burden of cancer disease in the country. As per the Canadian Cancer Statistics in 2015, about 196,900 people diagnosed with cancer.The data is important to focus on prevention efforts, in both primary prevention and secondary prevention of cancer, and allow more effective treatment of certain cancer through earlier detection.
Europe genitourinary drugs market will witness a significant growth over the forecast timeframe. It was estimated that over 78% of the new cancer medicines that were introduced between 2010 and 2014 are available within the greater EU. In 2012, Germany’s GDP accounted for over USD 34,706.8 per capita, driving the industry growth.
APAC should witness a lucrative growth during the forecast period owing to the increasing R&D in China and India, high disposable income, and growing awareness in these emerging countries.
Some of the companies operating in this industry include Abbott Laboratories, Astellas, Bayer, Bristol-Myers Squibb, Eli Lilly, Pfizer, Genentech, GlaxoSmithKline, Merck, Hoffman-La Roche, Immunex, and Ionis Pharmaceuticals.
High R&D expenditure by global players will drive industry innovation. Industry participants are developing novel products to gain competitive market leverage over their peers.
Companies are focusing on the implementation of strategies including mergers & acquisitions, new product development, and regional expansion. In October 2016, the U.S. FDA approved a supplemental Biologics License Application (sBLA) of Bristol-Myers Squibb, to enlarge the practice of Opdivo (nivolumab) to treat patients suffering from an advanced form of bladder cancer. Similarly, in June 2016, the U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP) and Bayer, collaborated on a new Phase III trial to study Stivarga (regorafenib) tablets as an adjuvant therapy in colon cancer. Growing geographical presence of the industry players is expected to raise the awareness levels regarding treatment options for genitourinary diseases among the patients and the doctors.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.